11:16 AM
 | 
Jan 19, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Galapagos reports Phase Ib data for GLPG1972 in OA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks were well tolerated. On a secondary endpoint,...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >